Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Total 13F shares
-
68,158,412
-
Share change
-
-2,717,131
-
Total reported value
-
$272,625,712
-
Put/Call ratio
-
172%
-
Price per share
-
$4.00
-
Number of holders
-
105
-
Value change
-
-$9,526,925
-
Number of buys
-
53
-
Number of sells
-
26
Institutional Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q3 2025
As of 30 Sep 2025,
ADC Therapeutics SA - Common Shares (ADCT) was held by
105 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
68,158,412 shares.
The largest 10 holders included
Redmile Group, LLC, Point72 Asset Management, L.P., Prosight Management, LP, ORBIMED ADVISORS LLC, BlackRock, Inc., MORGAN STANLEY, Nantahala Capital Management, LLC, GOLDMAN SACHS GROUP INC, TCG Crossover Management, LLC, and BANK OF AMERICA CORP /DE/.
This page lists
105
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.